| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Eosinophilic esophagitis: updated consensus recommendations for children and adults.
|
J Allergy Clin Immunol
|
2011
|
12.48
|
|
2
|
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment.
|
Gastroenterology
|
2007
|
9.05
|
|
3
|
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense.
|
Nat Med
|
2008
|
4.93
|
|
4
|
Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner.
|
Gastroenterology
|
2013
|
4.20
|
|
5
|
Eosinophilic esophagitis: escalating epidemiology?
|
J Allergy Clin Immunol
|
2005
|
3.13
|
|
6
|
Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
|
Am J Gastroenterol
|
2009
|
2.16
|
|
7
|
Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland.
|
J Allergy Clin Immunol
|
2011
|
2.07
|
|
8
|
Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate.
|
Am J Gastroenterol
|
2013
|
2.05
|
|
9
|
Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.
|
J Immunol
|
2002
|
1.82
|
|
10
|
Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.
|
Inflamm Bowel Dis
|
2009
|
1.65
|
|
11
|
Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation.
|
Am J Gastroenterol
|
2009
|
1.56
|
|
12
|
Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.
|
Inflamm Bowel Dis
|
2013
|
1.51
|
|
13
|
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease.
|
Inflamm Bowel Dis
|
2011
|
1.41
|
|
14
|
Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases.
|
J Allergy Clin Immunol
|
2005
|
1.13
|
|
15
|
Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
|
Inflamm Bowel Dis
|
2011
|
1.04
|
|
16
|
Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission.
|
Eur J Gastroenterol Hepatol
|
2007
|
1.04
|
|
17
|
Summary of the First International Gastrointestinal Eosinophil Research Symposium.
|
J Pediatr Gastroenterol Nutr
|
2007
|
1.03
|
|
18
|
Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis.
|
J Allergy Clin Immunol
|
2012
|
1.02
|
|
19
|
Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis.
|
J Allergy Clin Immunol
|
2008
|
1.01
|
|
20
|
Eosinophilic esophagitis: the endoscopist's enigma.
|
Gastrointest Endosc
|
2006
|
1.00
|
|
21
|
Induction of eosinophilic esophagitis by sublingual pollen immunotherapy.
|
Case Rep Gastroenterol
|
2013
|
0.91
|
|
22
|
Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome.
|
Eur J Immunol
|
2003
|
0.91
|
|
23
|
Placebo and other interventions in asthma.
|
N Engl J Med
|
2011
|
0.89
|
|
24
|
Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers.
|
J Crohns Colitis
|
2011
|
0.87
|
|
25
|
Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis.
|
J Allergy Clin Immunol
|
2010
|
0.87
|
|
26
|
Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals.
|
J Crohns Colitis
|
2010
|
0.86
|
|
27
|
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
|
Inflamm Bowel Dis
|
2015
|
0.84
|
|
28
|
Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes.
|
Digestion
|
2013
|
0.82
|
|
29
|
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
|
Inflamm Bowel Dis
|
2010
|
0.81
|
|
30
|
Cytotoxic T cells are preferentially activated in the duodenal epithelium from patients with florid coeliac disease.
|
J Pathol
|
2005
|
0.80
|
|
31
|
Treatment of eosinophilic esophagitis: diet, drugs, or dilation?
|
Gastroenterology
|
2012
|
0.80
|
|
32
|
Eosinophilic esophagitis and allergy.
|
Dig Dis
|
2014
|
0.79
|
|
33
|
Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.
|
Inflamm Bowel Dis
|
2015
|
0.78
|
|
34
|
[Status of alternative medicine in Crohn disease and ulcerative colitis patents: a questionnaire survey].
|
Forsch Komplementarmed Klass Naturheilkd
|
2005
|
0.77
|
|
35
|
Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
|
Inflamm Bowel Dis
|
2010
|
0.77
|
|
36
|
Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.
|
J Allergy Clin Immunol
|
2008
|
0.77
|
|
37
|
Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
|
Eur J Gastroenterol Hepatol
|
2017
|
0.76
|
|
38
|
Oral immunotherapy for egg allergy in children.
|
N Engl J Med
|
2012
|
0.76
|
|
39
|
Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation and anti-TNF Treatment.
|
J Pediatr Gastroenterol Nutr
|
2016
|
0.76
|
|
40
|
Eosinophilic Esophagitis: Impact of Latest Insights Into Pathophysiology on Therapeutic Strategies.
|
Dig Dis
|
2016
|
0.76
|
|
41
|
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
|
Inflamm Bowel Dis
|
2017
|
0.75
|
|
42
|
Eosinophilic esophagitis: from a sneaking suspicion to a clear diagnosis.
|
Digestion
|
2011
|
0.75
|
|
43
|
Long-Term Effiicacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
|
Dig Dis
|
2017
|
0.75
|
|
44
|
Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease.
|
J Pediatr Gastroenterol Nutr
|
2017
|
0.75
|
|
45
|
Endoscopic treatment of paraesophageal abscess in eosinophilic esophagitis after chest trauma.
|
Gastrointest Endosc
|
2011
|
0.75
|
|
46
|
Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.
|
Digestion
|
2010
|
0.75
|
|
47
|
Preface. Eosinophils and the digestive tract.
|
Best Pract Res Clin Gastroenterol
|
2008
|
0.75
|
|
48
|
Immunopathogenesis of eosinophilic esophagitis.
|
Dig Dis
|
2014
|
0.75
|